Regulation of the pro-inflammatory cytokine osteopontin by GIP in adipocytes - A role for the transcription factor NFAT and phosphodiesterase 3B

Biochemical and Biophysical Research Communications

Volumn 425, Issue 4, 2012, Pages 812-817

  Omar, Bilal ^a   Banke, Elin ^a   Guirguis, Emilia ^b   Åkesson, Lina ^c   Manganiello, Vincent ^b   Lyssenko, Valeriya ^c   Groop, Leif ^c   Gomez, Maria F ^c   Degerman, Eva ^a  

^a LUND UNIVERSITY   (Sweden)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Adipocytes; GIP; NFAT; Osteopontin; Phosphodiesterase 3B

Indexed keywords

5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLYCOGEN SYNTHASE KINASE 3; N CYCLOHEXYL 4 (1,2 DIHYDRO 2 OXO 6 QUINOLYLOXY) N (2 HYDROXYETHYL)BUTYRAMIDE; OSTEOPONTIN; PHOSPHODIESTERASE 3B; PHOSPHODIESTERASE III; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; LIPOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; UPREGULATION;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; GASTRIC INHIBITORY POLYPEPTIDE; INSULIN; LIPOGENESIS; MALE; MICE; NFATC TRANSCRIPTION FACTORS; OSTEOPONTIN; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY;

MUS;

EID: 84865991405     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.157     Document Type: Article

References (32)

1. Rasouli N., Kern P.A.J. Adipocytokines and the metabolic complications of obesity. Clin. Endocrinol. Metab. 2008, 93(11 Suppl. 1):S64-73.
2. Guilherme A., Virbasius J.V., Puri V., Czech M.P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell. Biol. 2008, 9:367-377.
3. Gutierrez D.A., Puglisi M.J., Hasty A.H. Impact of increased adipose tissue mass on inflammation, insulin resistance and dyslipidemia. Curr. Diab. Rep. 2009, 9:26-32.
4. Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444(7121):840-846. 14.
5. Kiefer F.W., Zeyda M., Todoric J., et al. Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology 2008, 149(3):1350-1357.
6. Gómez-Ambrosi J., Catalán V., Ramírez B., et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J. Clin. Endocrinol. Metab. 2007, 92(9):3719-3727.
7. Nomiyama T., Perez-Tilve D., Ogawa D., et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J. Clin. Invest. 2007, 117(10):2877-2888.
8. Kiefer F.W., Neschen S., Pfau B., et al. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia 2011, 54(8):2132-2142.
9. Chapman J., Miles P.D., Ofrecio J.M., et al. Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mce. PLoS One 2010, 5(11):e13959.
10. Kiefer F.X., Zeyda M., Gollinger K., et al. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 2010, 59(4):935-946.
11. McIntosh C.H., Widenmaier S., Kim S.J. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam. Horm. 2009, 80:409-471.
12. Yip R.G., Wolfe M.M. G.I.P. biology and fat metabolism. Life Sci. 2000, 66(2):91-103.
13. Miyawaki K., Yamada Y., Ban N., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 2002, 8(7):738-742.
14. Yip R.G., Boylan M.O., Kieffer T.J., Wolfe M.M. Functional GIP receptors are present on adipocytes. Endocrinology 1998, 139(9):4004-4007.
15. S. Mohammad, L.S. Ramos, J. Buck et al., Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110β isoform of phosphatidylinositol 3-kinase, J. Biol. Chem. 286 (50) (2011) 43062-43070.
16. V. Lyssenko, L. Eliasson, O. Kotova et al., Pleiotropic effects of GIP on islet function involve osteopontin. Diabetes 60 (9) (2011) 2424-2433.
17. Y.H. Choi, S. Park, S. Hockman et al., Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice, J. Clin. Invest. 116 (12) (2006) 3240-3251.
18. J.M. Trevillyan, X.G. Chiou, Y.W. Chen et al., Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds, Biol. Chem. 276 (51) (2001) 48118-48126.
19. Honnor R.C., Dhillon G.S., Londos C. CAMP-dependent protein kinase and lipolysis in rat adipocytes, I. Cell preparation, manipulation, and predictability in behavior. J. Biol. Chem. 1985, 260(28):15122-15129.
20. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
21. Moody A.J., Stan M.A., Stan M., Gliemann J. A simple free fat cell bioassay for insulin. Horm. Metab. Res. 1974, 6(1):12-16.
22. L.M. Nilsson-Berglund, A.V. Zetterqvist, J. Nilsson-Ohman et al., Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia, Arterioscler. Thromb. Vasc. Biol. 30 (2) (2010) 218-224.
23. G.R. Crabtree, E.N. Olson, NFAT signaling: choreographing the social lives of cells, Cell 109 (Suppl.) (2002) S67-S79.
24. Nilsson L.M., Nilsson-Ohman J., Zetterqvist A.V., Gomez M.F. Nuclear factor of activated T-cells transcription factors in the vasculature: the good guys or the bad guys?. Curr. Opin. Lipidol. 2008, 19(5):483-490.
25. C.R. Beals, C.M. Sheridan, C.W. Turck, P. Gardner, G.R. Crabtree, Nuclear Export of NF-ATc Enhanced by Glycogen Synthase Kinase-3, Science (275) (1997) 1930-1933.
26. Nilsson J., Nilsson L.M., Chen Y.W., et al. High glucose activates nuclear factor of activated T cells in native vascular smooth muscle. Arterioscler. Thromb. Vasc. Biol. 2006, 26(4):794-800.
27. Cross D.A., Watt P.W., Shaw M., et al. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue. FEBS Lett. 1997, 406(1-2):211-215.
28. D. Awla, A.V. Zetterqvist, A. Abdulla et al., NFATc3 regulates trypsinogen activation, neutrophil recruitment, and tissue damage in acute pancreatitis in mice, Gastroenterology (2012) (Epub ahead of print).
29. Zmuda-Trzebiatowska E., Manganiello V., Degerman E. Novel mechanisms of the regulation of protein kinase B in adipocytes; implications for protein kinase A, Epac, phosphodiesterases 3 and 4. Cell Signal. 2007, 19(1):81-86.
30. Zeyda M., Gollinger K., Todoric J., Kiefer F.W., Keck M., Aszmann O., Prager G., Zlabinger G.J., Petzelbauer P., Stulnig T.M. Osteopontin is an activator of human adipose tissue macrophages and directly affects adipocyte function. Endocrinology 2011, 152(6):2219-2227.
31. Nie Y., Ma R.C., Chan J.C., Xu H., Xu G. Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes. FASEB J. 2012, 26(6):2383-2393.
32. Holowachuk E.W. Nuclear factor of activated T cell (NFAT) transcription proteins regulate genes involved in adipocyte metabolism and lipolysis. Biochem. Biophys. Res. Commun. 2007, 361(2):427-432.